MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze AMGN →
    • FindStock Picks / Stock Screener
    • Value · AMGNIntrinsic Value Calculator
    • Invest · AMGNInvestment Case
    • Hold · AMGN5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AMGN stock logo

AMGN

Amgen Inc.

$465.67
-1.39
 (-0.3%)
Exchange:  NASDAQ
Market Cap:  251.886B
Shares Outstanding:  538M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Robert A. Bradway
Full Time Employees:  31500
Address: 
One Amgen Center Drive
Thousand Oaks
CA
91320-1799
US
Website:  https://www.amgen.com
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company’s scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen’s comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

AMGN full analysis

06/11/2026

Welcome back to MarketSnap. Amgen just beat earnings, raised guidance, and is up forty-four percent in a year — so why did it fall last week while the Dow hit a record? That's the contradiction I want to sit with today. The quarter was decisive: earnings of six forty-five a share against an estimate of five seventy-four, revenue up eight percent to ten point four billion, full-year guidance raised. And yet over the past week the stock slipped about two…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
AMAMGN logoAMGNAmgen Inc.251.9B26.819.815.6%
AZAZN logoAZNAstraZeneca PLC286.1B25.918.013.1%
GIGILD logoGILDGilead Sciences, Inc.208.5B——28.0%
NVNVS logoNVSNovartis AG303.1B30.818.014.0%
NVNVO logoNVONovo Nordisk A/S184.4B10.912.330.2%
PFPFE logoPFEPfizer Inc.164.7B40.99.58.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/03 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue28,190,00033,424,00036,741,000
Gross Profit19,775,00020,566,00026,012,000
EBITDA14,801,00013,356,00016,898,000
Operating Income7,897,0007,258,00010,676,000
Net Income6,717,0004,090,0007,711,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets97,154,00091,839,00090,586,000
Total Liabilities90,922,00085,962,00081,928,000
Total Stockholders Equity6,232,0005,877,0008,658,000
Total Debt64,613,00060,099,00054,604,000
Cash and Cash Equivalents10,944,00011,973,0009,129,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow8,471,00011,490,0009,958,000
Capital Expenditure-1,112,000-1,096,000-1,858,000
Free Cash Flow7,359,00010,394,0008,100,000
Net Income6,717,0004,090,0007,711,000
Net Change in Cash3,315,0001,029,000-2,844,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)45,972,649.637Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)49,520,191.561Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)47,305,410.306Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)24,359,262.201Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)26,241,261.593Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)25,066,304.095Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)16,265,062.310Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)17,911,029.593Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)16,883,430.111Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)9,522,604.931Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)10,257,429.669Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)9,798,668.056Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)31.150Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)33.050Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)30.010Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)13Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
33.232B  ?P/S
 (TTM)
: 
6.47
?Net Income
 (TTM)
: 
4.09B  ?P/E
 (TTM)
: 
26.79
?Enterprise Value
 (TTM)
: 
292.703B  ?EV/FCF
 (TTM)
: 
30.55
?Dividend Yield
 (TTM)
: 
2.14%  ?Payout Ratio
 (TTM)
: 
57.14%
?ROE
 (TTM)
: 
85.59%  ?ROIC
 (TTM)
: 
15.63%
?Net Debt
 (TTM)
: 
48.906B  ?Debt/Equity
 (TTM)
: 
3.76
?P/B
 (TTM)
: 
17.55  ?Current Ratio
 (TTM)
: 
1.48

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
19.77Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Q3 2026 results beat consensus decisively: EPS of $6.45 vs. $5.74 estimate (vs. $5.64 a year ago), with total revenue up 8% year-over-year to $10.4 billion; management raised full-year 2026 guidance to $38.9–39.7B revenue and $22.90–23.70 non-GAAP EPS.
  • Six key growth drivers rose 27% year-over-year and now represent over 70% of product sales, evidencing successful portfolio rotation; FY2025 revenue reached $36.7B (up ~10% from $33.4B in 2024) with net income of $7.7B and EPS of $14.33, a sharp rebound from 2024's $4.09B net income.
  • Strong profitability and cash generation: gross margin of 72.7% (TTM), net margin of 22.9%, ROE of 89.3%, ROIC of 14.2%, and quarterly free cash flow of $3.7B (FY2025 FCF of $8.1B).

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates AMGN intrinsic value between $416.24 – $531.47 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate AMGN Intrinsic Value

Common questions about AMGN valuation

Is Amgen Inc. (AMGN) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Amgen Inc. (AMGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AMGN a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AMGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AMGN’s P/E ratio?

You can see AMGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AMGN?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AMGN a good long-term investment?

Whether AMGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Amgen Inc.

  • Amgen Inc. intrinsic value calculatorEstimate what the business is worth
  • Amgen Inc. 5-year outlookWhat has to go right, and what could go wrong
AMGN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.3
MarketSnap

Trading Metrics:

Open: 467.53   Previous Close: 467.06
Day Low: 462.22   Day High: 468
Year Low: 312.39   Year High: 483.99
Price Avg 50: 424.87   Price Avg 200: 380.39
Volume: 1.478M   Average Volume: 2.731M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
13-11-2026 17:42
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
11-11-2026 10:06
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
Want $7,000 in Passive Income? Buy These 3 Dividend Stocks Today
11-11-2026 09:02
Want $7,000 in Passive Income? Buy These 3 Dividend Stocks Today
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?
10-11-2026 13:17
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
14-09-2026 10:01
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%
04-11-2026 13:16
Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze AMGN →
    • FindStock Picks / Stock Screener
    • Value · AMGNIntrinsic Value Calculator
    • Invest · AMGNInvestment Case
    • Hold · AMGN5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.